PepGen Inc. (NASDAQ:PEPG) is a top fast money stock to buy now with H.C. Wainwright reiterating a ‘Buy’ rating and raising the price target to $12.00, projecting a 135% surge. The company reported a 53.7% mean splicing correction in its FREEDOM single-dose study for DM1 patients, a record high in this patient group.

This significant splicing correction could lead to major functional improvements with repeat dosing, expanding PepGen Inc.’s therapeutic window to deliver real health benefits. The company’s outstanding financial performance, with a 34.04% return compared to the market average of 13.10%, showcases its potential for investors.

Headquartered in Boston, Massachusetts, PepGen Inc. (NASDAQ:PEPG) is a leading clinical-stage biotechnology firm specializing in oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Founded in 2018, the company offers innovative treatments like PGN-EDO51, PGN-EDODM1, and PGN-EDO53 to address critical medical needs in these areas.

While PepGen Inc. (NASDAQ:PEPG) shows promise as an investment, some AI stocks may offer greater upside potential with lower downside risk. Investors seeking undervalued AI stocks can explore opportunities in our free report on the best short-term AI stock. Explore more trends and stock insights in our other featured articles on market performance and investment opportunities.

Read more at Yahoo Finance: PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data